Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. 1997

J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
National Public Health Institute, Oulu, Finland.

The basic feature in the pathogenesis of abdominal aortic aneurysm (AAA) is the degradation of extracellular matrix components. This process is induced partly by cytokines secreted from inflammatory and mesenchymal cells. Circulating levels of inflammatory cytokines were studied in AAA patients and compared with subjects suffering from atherosclerotic disease only. Furthermore, the predictive value of cytokine concentrations was evaluated for aneurysm expansion rate. Circulating levels of interleukin 1 beta (IL-1 beta), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) were measured in 50 AAA patients (40 men, 10 women), 42 patients with coronary heart disease (CHD) (23 men, 19 women), and 38 controls whose angiogram was normal (17 men, 21 women). No differences in cytokine concentrations were found between the CHD patients and the controls. AAA disease was found to be associated with significantly higher IL-1 beta and IL-6 concentrations in both male patients (median concentrations of 19.40 pmol/L and 6.45 pmol/L, respectively) and female patients (19.26 pmol/L and 7.99 pmol/L) than in either the CHD patients or the controls (P < .005). TNF-alpha levels were slightly higher in the AAA patients (1.64 pmol/L in the males and 1.59 pmol/L in the females) than in the other groups (P < .05). IFN-gamma levels were elevated significantly in the female AAA patients (3.75 pmol/L) compared with levels found in the other female (P < .05) or male (P < .01) patient groups. The measured cytokine concentrations were not related to the size of the aneurysm or the maximal thickness of the thrombus within the aneurysm. IFN-gamma concentration showed a significant positive correlation to the aneurysm expansion (R = .37, P < .02) and negative correlation to the concentration of aminoterminal propeptide of type III procollagen during 6-month follow up (R = -.42, P < .005). The results show that circulating levels of inflammatory cytokines are elevated in patients with AAA disease, suggesting that the production of these cytokines is increased in these patients compared with CHD patients and controls. Elevated INF-gamma concentrations seem to predict an increased rate of expansion in AAA.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females

Related Publications

J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
November 2006, Annals of the New York Academy of Sciences,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
January 2000, Journal of vascular and interventional radiology : JVIR,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
May 2000, Angiology,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
February 2017, Angiology,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
August 2005, The Israel Medical Association journal : IMAJ,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
May 2006, Anales de medicina interna (Madrid, Spain : 1984),
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
January 2007, JAMA,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
October 1998, Circulation,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
May 1986, Surgery, gynecology & obstetrics,
J Juvonen, and H M Surcel, and J Satta, and A M Teppo, and A Bloigu, and H Syrjälä, and J Airaksinen, and M Leinonen, and P Saikku, and T Juvonen
April 2000, Journal des maladies vasculaires,
Copied contents to your clipboard!